The impact of azole resistance on aspergillosis guidelines

Annals of the New York Academy of Sciences

Volumn 1272, Issue 1, 2012, Pages 15-22

  Georgiadou, Sarah P ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aspergillus, resistance; Azoles; Guidelines

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 51A; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; FUNGAL STRAIN; HUMAN; IN VITRO STUDY; NOMENCLATURE; NONHUMAN; PRACTICE GUIDELINE;

EID: 84870926977     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06795.x     Document Type: Article

References (65)

1. Ananda-Rajah, M.R., M.A. Slavin & K.T. Thursky 2012. The case for antifungal stewardship. Curr. Opin. Infect. Dis 25: 107-115.
2. Walsh, T.J., E.J. Anaissie, D.W. Denning, et al 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46: 327-360.
3. Verweij, P.E., S.J. Howard, W.J. Melchers, et al 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Update 12: 141-147.
4. Pfaller, M.A., D.J. Diekema, J.H. Rex, et al 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44: 819-826.
5. Bowyer, P., C.B. Moore, R. Rautemaa, et al 2011. Azole antifungal resistance today: focus on Aspergillus. Curr. Infect. Dis. Rep. 13: 485-491.
6. Camps, S.M., J.W. van der Linden, Y. Li, et al 2012. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob. Agents Chemother. 56: 10-16.
7. Chen, J., H. Li, R. Li, et al 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother 55: 31-37.
8. Howard, S.J., I. Webster, C.B. Moore, et al 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28: 450-453.
9. Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, et al 2004. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48: 2747-2750.
10. Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, et al 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51: 1897-1904.
11. Snelders, E., H.A. van der Lee, J. Kuijpers, et al 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5: e219.
12. Verweij, P.E., E. Mellado & W.J. Melchers 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356: 1481-1483.
13. Liu, W., Y. Sun, W. Chen, et al 2012. T778G mutation in cyp51C gene confers voriconazole-resistance in Aspergillus flavus causing aspergillosis. Antimicrob. Agents Chemother 56: 2598-2603.
14. Slaven, J.W., M.J. Anderson, D. Sanglard, et al 2002. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet. Biol. 36: 199-206.
15. Manavathu, E.K., J. Cutright & P.H. Chandrasekar 1999. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents. J. Clin. Microbiol. 37: 858-861.
16. Dannaoui, E., E. Borel, F. Persat, et al 1999. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus. J. Med. Microbiol. 48: 1087-1093.
17. Chamilos, G. & D.P. Kontoyiannis 2005. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist. Update 8: 344-358.
18. Pfaller, M.A., L. Boyken, R.J. Hollis, et al 2009. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol. 47: 3323-3325.
19. Pfaller, M.A., L. Boyken, R.J. Hollis, et al 2010. Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. Diagn. Microbiol. Infect. Dis. 67: 56-60.
20. Steinbach, W.J., D.K. Benjamin, Jr., D.P. Kontoyiannis, et al 2004. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis. 39: 192-198.
21. Kontoyiannis, D.P., R.E. Lewis, G.S. May, et al 2002. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 45: 406-407.
22. Varga, J., J. Houbraken, H.A. Van Der Lee, et al 2008. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot. Cell 7: 630-638.
23. Balajee, S.A., J.L. Gribskov, E. Hanley, et al 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4: 625-632.
24. Egli, A., J. Fuller, A. Humar, et al 2012. Emergence of Aspergillus calidoustus infection in the era of posttransplantation azole prophylaxis. Transplantation 94: 403-410.
25. Howard, S.J., E. Harrison, P. Bowyer, et al 2011. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob. Agents Chemother. 55: 4802-4809.
26. Perlin, D.S. 2009. Antifungal drug resistance: do molecular methods provide a way forward? Curr. Opin. Infect. Dis. 22: 568-573.
27. Bueid, A., S.J. Howard, C.B. Moore, et al 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65: 2116-2118.
28. Kuipers, S., R.J. Bruggemann, R.G. de Sevaux, et al 2011. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob. Agents Chemother. 55: 3564-3566.
29. Tarrand, J.J., M. Lichterfeld, I. Warraich, et al 2003. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am. J. Clin. Pathol. 119: 854-858.
30. Tarrand, J.J., X.Y. Han, D.P. Kontoyiannis, et al 2005. Aspergillus hyphae in infected tissue: evidence of physiologic adaptation and effect on culture recovery. J. Clin. Microbiol. 43: 382-386.
31. Muller, F.M., M. Seidler & A. Beauvais 2011. Aspergillus fumigatus biofilms in the clinical setting. Med. Mycol. 49 (Suppl 1): S96-S100.
32. Willger, S.D., S. Puttikamonkul, K.H. Kim, et al 2008. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog. 4: e1000200.
33. Howard, S.J., et al 2012. Microevolution of Aspergillus Fumigatus in aspergillomas. In 5th Advances Against Aspergillosis, P-124, Istanbul, Turkey
34. Denning, D.W., S. Park, C. Lass-Florl, et al 2011. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin. Infect. Dis. 52: 1123-1129.
35. Howard, S.J., D. Cerar, M.J. Anderson, et al 2009. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15: 1068-1076.
36. van der Linden, J.W., E. Snelders, G.A. Kampinga, et al 2011. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg. Infect. Dis. 17: 1846-1854.
37. Verweij, P.E., D.T. Te Dorsthorst, A.J. Rijs, et al 2002. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J. Clin. Microbiol. 40: 2648-2650.
38. Snelders, E., S.M. Camps, A. Karawajczyk, et al 2012. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One 7: e31801.
39. Mortensen, K.L., E. Mellado, C. Lass-Florl, et al 2010. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54: 4545-4549.
40. Snelders, E., R.A. Huis In 't Veld, A.J. Rijs, et al 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75: 4053-4057.
41. Verweij, P.E., E. Snelders, G.H. Kema, et al 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9: 789-795.
42. Klaassen, C.H., J.G. Gibbons, N.D. Fedorova, et al 2012. Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogen Aspergillus fumigatus. Mol. Ecol. 21: 57-70.
43. Morio, F., G.G. Aubin, I. Danner-Boucher, et al 2012. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J. Antimicrob. Chemother. 67: 1870-1873.
44. Pelaez, T., P. Gijon, E. Bunsow, et al 2012. Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis. J. Clin. Microbiol. 50: 2531-2534.
45. Snelders, E., A. Karawajczyk, G. Schaftenaar, et al 2010. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob. Agents Chemother. 54: 2425-2430.
46. Van der Linden, J.W. M. et al 2011. Prospective International Surveillance of Azole Resistance in Aspergillus fumigatus. SCARE-Network In ICAAC, M-490, San Francisco, USA
47. Pfaller, M., L. Boyken, R. Hollis, et al 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J. Clin. Microbiol. 49: 586-590.
48. Lockhart, S.R., J.P. Frade, K.A. Etienne, et al 2011. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55: 4465-4468.
49. Lewis, J.S., 2nd & J.R. Graybill 2008. Fungicidal versus Fungistatic: what's in a word? Expert Opin. Pharmacother. 9: 927-935.
50. Kontoyiannis, D.P., K.A. Marr, B.J. Park, et al 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50: 1091-1100.
51. Planche, V., S. Ducroz, A. Alanio, et al 2012. In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp. Antimicrob. Agents Chemother. 56: 4500-4503.
52. Jeans, A.R., S.J. Howard, Z. Al-Nakeeb, et al 2012. Combination of voriconazole and anidulafungin for the treatment of triazole resistant Aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother 56: 5180-5185.
53. Krishnan-Natesan, S., W. Wu & P.H. Chandrasekar 2012. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 73: 135-137.
54. van der Linden, J.W., E. Snelders, J.P. Arends, et al 2010. Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. J. Clin. Microbiol. 48: 1478-1480.
55. Spiess, B., W. Seifarth, N. Merker, et al 2012. Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients. Antimicrob. Agents Chemother. 56: 3905-3910.
56. Koo, S., J.M. Bryar, L.R. Baden, et al 2010. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J. Clin. Microbiol. 48: 1255-1260.
57. Miceli, M.H., M.L. Grazziutti, G. Woods, et al 2008. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin. Infect. Dis. 46: 1412-1422.
58. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. October 14, 2011; 1-167: Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdoles-centGL.pdf.
59. Miceli, M.H., J.A. Diaz & S.A. Lee 2011. Emerging opportunistic yeast infections. Lancet Infect. Dis. 11: 142-151.
60. Campo, M., R.E. Lewis & D.P. Kontoyiannis 2010. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J. Infect. 60: 331-337.
61. Rodriguez-Tudela, J.L., J. Berenguer, J. Guarro, et al 2009. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med. Mycol. 47: 359-370.
62. Blumental, S., R. Mouy, N. Mahlaoui, et al 2011. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin. Infect. Dis. 53: e159-169.
63. Lass-Florl, C., K. Griff, A. Mayr, et al 2005. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br. J. Haematol. 131: 201-207.
64. Hachem, R.Y., D.P. Kontoyiannis, M.R. Boktour, et al 2004. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101: 1594-1600.
65. Espinel-Ingroff, A., D.J. Diekema, A. Fothergill, et al 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48: 3251-3257.